Photocure fundamentale forhold (PHO)

[TheObserver]

Jeg har delt om lovverket, det er 100 % klart. Av respekt for at dette ikke er småprat, har jeg ikke flere svar hvis noen vil kverulere eller bende det i ønsket retning.

[M73102]

Nå må du gi deg, TheObserver - du har ikke delt noe som helst fra lovverket, og har kun kommet med bastante påstander som virker å være basert på AI. Hva mener du er 100 % klart? Med all mulig respekt å melde - du virker å ha lite kunnskap om de rettslige aspektene og hvordan en anvender juridisk metode for å klargjøre innholdet i reglene.

[Fso]

Sikke en masse skriv i den forkerte tråd

[TekBot]

Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.

Press Release - Oslo, Norway, August 11, 2026: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces the publication of the "Healthcare Resource
Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy
…

Vis børsmeldingen

in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study" in JU Open
Plus this week. The research objective was to evaluate the economic implications
of blue light cystoscopy (BLC[®]) versus white light cystoscopy (WLC) with
Hexvix[®]/Cysview[®] in a real-world setting, using claims data from the U.S.
Optum Research Database.

The study authors described the background as follows: “Bladder cancer remains
one of the most commonly diagnosed malignancies worldwide, ranking among the top
ten cancers in incidence and contributing significantly to morbidity and
mortality. Blue light cystoscopy improves detection of non muscle-invasive
bladder cancer (NMIBC), particularly carcinoma in situ (CIS), compared to white
light cystoscopy. However, the impact of BLC on healthcare resource utilization
and costs remains unclear. This study evaluates the economic implications of BLC
versus WLC in a real-world setting.”

Methodology: A retrospective cohort analysis was conducted using claims data
from the Optum Research Database. Patients undergoing BLC or WLC between June 1,
2011, and May 31, 2023, were included, permitting. A total of 794 BLC patients
and 4,764 matched WLC patients were analyzed. Healthcare resource utilization
and total and bladder cancer specific costs were assessed using per-patient-per
-month (PPPM) measures in inflation-adjusted 2023 USD.

Key findings: During the baseline period, prior to index cystoscopy, BLC
patients had higher prevalence of CIS detection than WLC per reimbursement
claims. BLC patients also underwent more upper tract imaging and biomarker
testing. BLC patients were shown to have significantly higher bladder cancer
-related ambulatory visits compared to WLC. Despite increased ambulatory
utilization, total healthcare costs PPPM were not significantly different
between BLC and WLC cohorts for all cause costs ($2,987.93 vs. $2,886.16,
p=0.65) nor bladder cancer specific costs ($1,301.10 vs. $1,246.60, p=0.75).

The authors conclude that BLC increases detection of CIS and leads to more
frequent surveillance and interventions. However, these do not translate into
significantly higher healthcare costs in an Inverse Probability of Treatment
Weighting (IPTW) model with variable patient follow-up. Given its cost-neutral
profile, BLC remains a valuable diagnostic tool in NMIBC management. Further
research should assess its long-term oncologic and economic impact.

“These real-world results are encouraging. They contribute to the clinical
utility of blue light cystoscopy (BLC) for NMIBC patients - as the BRAVO real
world-study demonstrated - and demonstrate cost-neutrality of the procedure. BLC
will continue to play an important role in improving quality of NMIBC
diagnostics and care. Optimizing diagnostic strategies to maximize the accuracy
of initial diagnosis and follow-up can impact costs and lead to improved patient
outcomes,” said Mark Tyson, the study’s principal investigator.

Read the full publication here:
Health Care Utilization and Costs Associated With Blue-Light vs White-Light Cystoscopy: A Real-World Bladder Cancer Population - PMC

For more information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Priyam Shah
Vice President Investor Relations
Tel : +17176815072
Email: priyam.shah@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 949 000 prevalent cases (5-year prevalence rate)[1a],
614 000 new cases and more than 220 000 deaths in 2022.[1b]
Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]

[1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [February 2024].
[2 ]Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3 ]Sievert KD et al. World J Urol 2009;27:295-300
[4 ]Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S.
and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.
The following safety information is solely included to comply with U.S.
regulatory requirements: Important Risk & Safety Information for Cysview[®]
(hexaminolevulinate HCl) (https://packageinsert.s3.us-east
-2.amazonaws.com/Cysview+PI+2020.pdf)

About Photocure ASA
Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news

Kilde

[TekBot]

Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II

Oslo, Norway, August 14, 2026 - Photocure ASA (OSE: PHO), the Bladder Cancer
Company, today announced that the U.S. Food and Drug Administration (FDA) has
published a proposed order (https://public-inspection.federalregister.gov/2026
…

Vis børsmeldingen

-16728.pdf) in the Federal Register to initiate the process of reclassifying
cystoscopic systems intended as an aid for the detection of bladder cancer from
Class III to Class II.

Importantly, FDA is initiating the proposed reclassification on its own
initiative following its review of available scientific, clinical and post
-market evidence. FDA states that there is sufficient information to establish
special controls that, together with general controls, will provide reasonable
assurance of the safety and effectiveness of these devices.

The proposed reclassification applies to cystoscopic systems intended for use
with an approved optical imaging agent for photodynamic blue light cystoscopy
(BLC[®]) as an adjunct to white light cystoscopy (WLC) for the detection of
known or suspected bladder cancer, including carcinoma in situ, and for patients
undergoing surveillance cystoscopy for bladder cancer.

“As indicated in the April 13 update (404: Not found
-asa-update-on-regulatory-classification-for-oay-equipment-5341345) on the
regulatory classification for OAY equipment, this is a very important regulatory
milestone for Photocure, physicians, and the bladder cancer community,” said Dan
Schneider, President and Chief Executive Officer of Photocure. “FDA’s decision
to initiate the reclassification process on its own initiative reflects the
Agency’s conclusion that there is sufficient information to establish special
controls for these devices and provide important regulatory recognition of the
established safety and effectiveness of BLC. We believe the proposed framework
is much better aligned with the technology’s longstanding clinical use and
regulatory experience and will serve as a tremendous catalyst for the U.S.
business.”

A Significant Opportunity to Expand BLC Access in the United States

BLC with Cysview[®] is an established adjunct to WLC for the detection of non
-muscle invasive bladder cancer (NMIBC). Cysview is an FDA-approved optical
imaging agent that is instilled into the bladder prior to cystoscopy and enables
malignant lesions to fluoresce under blue light, helping physicians visualize
bladder cancer lesions that may not be visible under white light alone.

FDA’s proposed reclassification follows its review of the regulatory and
clinical history of these systems, including data from the original PMA, peer
-reviewed literature, the FDA’s 2009 Oncologic Drugs Advisory Committee meeting
regarding Cysview, and available post-market safety information and subsequent
submissions. FDA concluded that the available information supports establishing
special controls for the device category and noted a lack of significant post
-market safety signals.

When finalized, the proposed reclassification would move applicable cystoscopic
systems from the current Class III premarket approval (PMA) pathway to Class II
with special controls and premarket notification under the 510(k) pathway. FDA
is not proposing to exempt these devices from 510(k) requirements but is
proposing a new device class (Cystoscopic system intended as an aid for
detection of bladder cancer).

“We welcome FDA’s initiative to establish a regulatory framework that reflects
the maturity of BLC and its established clinical use,” said Dr. Anders Neijber,
Chief Medical Officer of Photocure. “We look forward to working with additional
physicians, technology partners and other stakeholders to significantly expand
access to BLC with Cysview for patients across the United States.”

Supporting Innovation and Expanded Access

Photocure believes that, when finalized, the reclassification will facilitate
meaningful innovation and the development and introduction of additional
standalone and add-on cystoscopic equipment platforms in the United States using
BLC as the foundational technology.

Greater availability of compatible equipment will provide all hospitals and
physicians with the opportunity to incorporate BLC into clinical practice and
complement ongoing efforts to expand patient access, generate clinical and
health-economic evidence, and support broader adoption of technology.

“The proposed transition to Class II will support greater innovation and
significantly broaden the availability of BLC in the United States,” said Geoff
Coy, Vice President and General Manager North America at Photocure. “Additional
equipment platforms will give more hospitals and physicians the opportunity to
incorporate BLC into their clinical practice and accelerate adoption of this
established technology for bladder cancer patients, as we have seen with
expanded access through our mobile solution collaboration with ForTec.”

The FDA’s proposed reclassification remains subject to the applicable regulatory
process, including a public comment period and FDA consideration of comments
before any final order is issued. Until a final order becomes effective, the
applicable cystoscopic systems remain subject to their current regulatory
classification and requirements.

For more information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Priyam Shah
Vice President Investor Relations
Tel: +17176815072
Email: priyam.shah@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 949 000 prevalent cases (5-year prevalence rate)[1a],
614 000 new cases and more than 220 000 deaths in 2022.[1b]
Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five
years.[2] Bladder cancer has the highest lifetime treatment costs per patient of
all cancers.[3]
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]

[1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [February 2024].
[2 ]Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3 ]Sievert KD et al. World J Urol 2009;27:295-300
[4 ]Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html

About BLC[®] with Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S.
and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.
The following safety information is solely included to comply with U.S.
regulatory requirements: Important Risk & Safety Information for
Cysview (https://packageinsert.s3.us-east
-2.amazonaws.com/Cysview+PI+2020.pdf)[®] (hexaminolevulinate
HCl) (https://packageinsert.s3.us-east-2.amazonaws.com/Cysview+PI+2020.pdf)

About Photocure ASA
Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news

Kilde

[h3nk1]

Dette er en kjøttfull melding, endelig. Kan hende en bakenforliggende årsak til den tilsynelatende aversjonen mot å kutte særlig i US-riggen.

Edit:

Feil tråd

[kreinh]

Asieris Pharmaceuticals’ bærbare, fleksible cystoskop med blått lys APLD-2304 får EU CE-merket

27. august 2026
    Pressemelding
    Shanghai, Kina, 27. august 2026

— Asieris Pharmaceuticals (aksjekode: 688176.SH), et globalt, innovativt farmasøytisk selskap med fokus på svulster i kjønnsorganer og kvinners helse, kunngjorde at deres uavhengig utviklede, bærbare, fleksible cystoskop med blått lys APLD-2304 nylig har fått EU MDR CE-merket, noe som gir markedsadgang i EU. APLD-2304 er verdens første bærbare, fleksible cystoskop med blått lys til engangsbruk, utviklet av selskapet for å imøtekomme de kliniske behovene og bruksscenariene for diagnose av blærekreft og oppfølgingsovervåking[1].

Drevet av en aldrende befolkning og høy røykerate står Europa overfor en høy årlig forekomst av blærekreft, som overstiger 130 000 nye tilfeller[2]. Den høye tilbakefallsraten av sykdommen skaper et stort udekket behov for langsiktig postoperativ pasientovervåking. APLD-2304 utnytter fordelen med blålysavbildning for å identifisere ørsmå lesjoner og karsinom in situ, og har et betydelig potensial i markedet for overvåking av blærekreft.

I klinisk praksis i Europa og USA brukes hvitlyscystoskopi ofte til diagnose og oppfølging av blærekreft. Likevel klarer den ofte ikke å oppdage flate eller små perifere lesjoner i tidlig stadium, noe som fører til lave deteksjonsrater og høye tilbakefallsrater. Selskapets APLD 2304, brukt i kombinasjon med et blålysavbildningsmiddel Hexvix®, danner en integrert diagnostisk løsning for legemidler for blærekreft. Denne løsningen forbedrer deteksjonsraten for blærekreft, reduserer tilbakefallsraten for pasienter, og den bærbare, fleksible, sterile engangsdesignen gir større bekvemmelighet for leger, forbedrer pasientkomforten under kirurgiske inngrep og reduserer risikoen for kryssinfeksjon.

Denne CE-sertifiseringen for APLD 2304 ble utstedt av EUs varslede organ (BSI Group The Netherlands B.V.) i samsvar med sertifiseringsreglene i forskriften om medisinsk utstyr (MDR), sammen med et kvalitetssystemsertifikat i henhold til ISO 13485:2016. Dette er første gang et selskapsutviklet produkt har fått regulatorisk registrering i EU, noe som betyr at Asieris har etablert et kvalitetsstyringssystem for medisinsk utstyr som overholder EUs MDR-krav. APLD 2304 oppfyller de nyeste kriteriene for markedsadgang i EU og kan selges i regioner som anerkjenner EUs forskrifter for medisinsk utstyr. I tillegg har APLD-2304 fulle uavhengige immaterielle rettigheter, og flere patentsøknader for dette produktet er innlevert både nasjonalt og internasjonalt.

Richard Zhao, Senior Vice President of Business Development hos Asieris Pharmaceuticals, uttalte: «EUs CE-merke for APLD 2304 er et viktig skritt i vårt strategiske fokus på spesialiserte kliniske felt og vår omfattende planlegging for helhetlig behandling av blærekreft. Det understreker også Asieris’ sterke forpliktelse til å håndtere kritiske udekkede globale kliniske behov. Vi vil fortsette å drive utviklingen av kliniske behandlingsprotokoller, levere innovative løsninger for pasienter og heve de diagnostiske og terapeutiske standardene for blærekreft.»

[Jubel]

Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex...

• October 7, 2026

• News Release

• Agreement is expected to grants Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for the rest of the world.

• The deal includes 15 million US dollars of upfront payment and a total of 11 million dollars of near-term regulatory milestone payments ， and commercial milestone payments as well as tiered royalties. The total deal value is in excess of 250 million US dollars.

• The upfront payment is subject to a few conditions, which include the signing of a supply agreement, successful audits of CEVIRA® manufacturing sites, streamline this agreement with the upstream licensing agreement, and a clarification with European Commission for around the clinical value assessment of the CEVIRA® device.

SHANGHAI, China and LONDON, UK — Oct 7. 2026 — Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative therapies for the treatment of genitourinary tumors and gynecological diseases, and Theramex, a global specialty pharmaceutical company dedicated to women and their health, today announced that they have entered into an exclusive licensing agreement for CEVIRA®(APL-1702) covering all countries in Europe, as well as Australia, New Zealand and Turkey. Asieris retains the rights for the rest of the world.

APL-1702 is a photodynamic drug-device combination product being developed as a non-surgical treatment for cervical precancerous lesions associated with HPV, including cervical intraepithelial neoplasia. The product is designed to be administered by a healthcare professional in an office-based setting and may provide a local treatment option for appropriate women who would otherwise be considered for surgical procedures. By offering a non-surgical approach designed to preserve cervical tissues, APL-1702 has the potential to address a highly unmet clinical need for non-surgical treatments globally.

The deal includes 15 million US dollars of upfront payment and a total of 11 million dollars of near-term regulatory milestone payments, and commercial milestone payments as well as tiered royalties. The total deal value is in excess of 250 million US dollars. The upfront payment is subject to a few conditions, which include the signing of a supply agreement, successful audits of CEVIRA®manufacturing sites, streamline this agreement with the upstream licensing agreement, and a clarification with European Commission for around the clinical value assessment of the CEVIRA®device.

In March 2026, Asieris announced that CEVIRA® had received approval from China’s National Medical Products Administration as a first-in-class non-invasive therapy for cervical precancerous lesions.

[Jubel]

Asieris Enters an Exclusive Licensing Agreement with Theramex for CEVIRA |...

[TekBot]

Photocure ASA: Invitation to presentation of third quarter 2026 financial results

Oslo, Norway, 20 October 2026: Photocure ASA (Photocure, PHO: OSE) will announce
the third quarter 2026 financial results on Wednesday 28 October 2026 at 08:00
CET and will present a live webcast at 14:00 CET the same day.
…

Vis børsmeldingen

The quarterly report and presentation will be published at 08:00 CET and will be
publicly available at www.photocure.com.

The investor presentation will be streamed live and hosted by Dan Schneider,
CEO, Priyam Shah, VP of Investor Relations and Dick Peters, VP Finance & IT. The
presentation will be held in English and questions can be submitted throughout
the event. The presentation is scheduled to conclude at 14:45 CET.

The streaming event is available through https://qcnl.tv/p/HeiCuy
-mR7EVvAyoiKXpOA (https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F
%2Fqcnl.tv%2Fp%2FHeiCuy
-mR7EVvAyoiKXpOA&data=05%7C02%7CTH%40photocure.no%7C8d5eff7f3dbf42f654fe08df2db60
9c0%7C0986794f1d6f488980bd853c0715d3c1%7C0%7C0%7C639279932038277080%7CUnknown%7CT
WFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTW
FpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=BjDyOesqZOP1SOPZFeT7ahPjuhItu%2BD%2BBbr
qY8m65js%3D&reserved=0).

For further information, please contact:

Photocure
Priyam Shah
Vice President of Investor Relations
Tel: +17176815072
Email: priyam.shah@photocure.com

Media enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure
Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news

This information is subject to the disclosure requirements pursuant to Section 5
-12 the Norwegian Securities Trading Act.

Kilde

[TekBot]

Photocure ASA - New CFO Appointed

Oslo, Norway, October 22, 2026: Photocure ASA (OSE: PHO), the Bladder Cancer
Company, is today announcing that Dennis Camporeale has been appointed as Chief
Financial Officer, effective on Monday, October 26, 2026.
…

Vis børsmeldingen

Dennis Camporeale brings 25 years of experience as senior healthcare investment
banker and corporate finance leader across life science tools, diagnostics,
medtech and broader healthcare. He most recently led the Life Science Tools and
Diagnostics practice at Canaccord Genuity, advising boards and executive teams
on capital raising, M&A, restructuring and strategic development. Alongside his
advisory background, Mr. Camporeale brings meaningful operational experience
from Ally Financial, where he helped transform GMAC from a captive finance
subsidiary into a standalone public company. He supported the company’s
successful US IPO, international divestments and the development of the
financial controls, governance structures and reporting processes required for a
publicly listed organisation.

“I am delighted to welcome Dennis to Photocure as our new CFO. His experience
across medtech, diagnostics and broader life sciences investment banking brings
a valuable combination of industry insight, financial expertise and strategic
perspective to the company,” said Dan Schneider, CEO of Photocure. “As we
continue to advance our growth strategy and broaden our reach to unlock the full
potential of our emerging portfolio, Dennis’s experience will be instrumental in
helping us execute our ambitions and create long-term value for patients,
partners and shareholders.”

For more information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Priyam Shah
Vice President Investor Relations
Tel: +17176815072
Email: priyam.shah@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act and Euronext Oslo Rule Book II -
Issuer Rules.

Kilde

[solskimm]

@TekBot

He supported the company’s
successful US IPO,

Mon tro om dette kan være aktuelt for Pho på sikt? Det har jo blitt et markant mer US-selskap de siste årene?

[Phsykes88]

Jeg håper vi kan bli lønnsomme før vi vurderer dette. Nå bør fokuset være å kapitalisere på alle investeringene vi har utestående tenker jeg, så kan vi heller vurderer listing over dammen når vi har litt vind i seilene og betydelig bedre lønnsomhet

[Haltopen]

Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2026 Third Quarter Report

https://guba.eastmoney.com/news,688176,1787996216.html

[TekBot]

Photocure ASA - Share option grant to new CFO

Oslo, Norway, 27 October 2026 - Photocure ASA (OSE: PHO) has issued 200,000
share options to its new Chief Financial Officer, Mr. Dennis Camporeale at an
exercise price of NOK 54.98 per share. The exercise price is equal to the
…

Vis børsmeldingen

weighted average share price 30 trading days before day of grant with an
additional premium of 10% on top of the calculated average price.

The options are granted in accordance with Photocure’s long term incentive
program and the company’s guidelines for remuneration of senior executives, as
approved by Photocure’s annual general meeting held 26 June 2026. The share
option program and properties of the options are further described in the
guidelines.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For more information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Priyam Shah
Vice President Investor Relations
Tel: +17176815072
Email: priyam.shah@photocure.com

About Photocure AS

Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

[TekBot]

Photocure ASA: Results for the third quarter of 2026

Oslo, Norway, 28 October 2026 - Photocure ASA (OSE:PHO) today reported
Hexvix®/Cysview® revenues of NOK 134.2 million in the third quarter of 2026 (Q3
2025: NOK 134.1 million), and Adjusted EBITDA of NOK 18.5 million (Q3 2025: NOK
…

Vis børsmeldingen

18.9 million). In 2026, Photocure now expects product revenue growth in the
range of 10% to 12% on a constant currency basis (versus 8 to 11% previously)
and adjusted EBITDA margin expansion.

“Photocure is progressing toward an important evolution in its development:
building on an established commercial franchise while expanding our capabilities
across the bladder cancer diagnostic pathway. Our ambition is to combine the
reach of Hexvix / Cysview with non-invasive molecular diagnostics, advanced
imaging, artificial intelligence and real-world clinical evidence. We believe
these complementary capabilities can create new opportunities to improve patient
care, expand our addressable market and deliver sustainable long-term growth,”
says Dan Schneider, President & Chief Executive Officer of Photocure.

The company continued to execute on its plan to expand blue-light cystoscopy
(BLC®) use in Q3 2026 with the installation of 13 new Saphira tower
installations in the U.S., including 9 installations in new accounts and 4
upgrades. Photocure had 454 active accounts in the U.S. at the end of the
quarter, an increase of 20% versus the third quarter of 2025. Across Europe, a
total of 87 Olympus Visera Elite III BLC capable systems were installed since
the launch in Q1 2025 along with 29 upgraded rigid systems YTD from Karl Storz,
Richard Wolf and Stryker.

Total revenues were NOK 140.9 million in the third quarter of 2026, an increase
from NOK 135.0 million in Q3 2025. Reported EBITDA was NOK 4.0 million (NOK 10.2
million). EBIT was NOK -3.4 million (NOK 2.9 million). Cash and cash equivalents
were NOK 162.4 million at the end of the period.

“We have also strengthened Photocure’s leadership team with the appointment of
Dennis Camporeale as our new Chief Financial Officer. Dennis has a strong
background in medtech and diagnostics investment banking, spanning mergers and
acquisitions, strategic advisory, business development and corporate finance.
This appointment supports our focus on disciplined financial management and
execution while we advance our commercial franchise and invest in growth
opportunities across the bladder cancer diagnostic pathway,” Schneider says,
continuing:

“An important catalyst for our core business is the U.S. Food and Drug
Administration’s proposal to reclassify applicable BLC systems from Class III to
Class II. Published in August, the proposal will establish a new regulatory
framework with special controls and a 510(k) pathway, subject to the FDA’s final
determination. We believe this evolution will facilitate broader participation
by equipment manufacturers, expand the availability of compatible BLC platforms
and support wider adoption of BLC across U.S. healthcare systems. Combined with
our commercial infrastructure and mobile access model, the reclassification will
create a meaningful opportunity to accelerate market development and strengthen
our position in bladder cancer diagnostics.”

Photocure continues to build a stronger body of clinical and economic evidence
to support BLC adoption in the United States. Recent publications using U.S.
real-world data have demonstrated cost neutrality between BLC and white light
cystoscopy (WLC) in the studied population and highlighted opportunities to
improve the prediction of bladder cancer recurrence and progression in
contemporary patients treated with BLC. Photocure’s growing Cysview registry
provides a valuable foundation for understanding patient outcomes and developing
more individualized approaches to disease management. The evidence-generation
capability of the registry will serve as an increasingly important strategic
asset, supporting clinical engagement today while creating opportunities for
future predictive analytics and data-driven diagnostics.

“Following the acquisition of Vesica Health, AssureMDx is our second growth
engine and serves as a significant step in extending our reach earlier in the
patient pathway through a multi-omic, urine-based molecular test designed to
support risk stratification and the evaluation of patients presenting with
hematuria. By combining non-invasive molecular testing via AssureMDx with our
established BLC franchise, we can connect earlier risk assessment with
procedural diagnosis and subsequent patient management. We expect initial
AssureMDx revenue in 2027, with reimbursement secured during the first half of
2027,” Schneider added.

“Artificial intelligence provides another opportunity to extend our capabilities
and differentiate our offering. Through our work with Claritas HealthTech and
its subsidiary Intelligent Scopes Corporation, we are advancing AI-enabled
technology designed to support physicians during BLC procedures, with the
potential to enhance tumor detection and resection completeness. The Photocure
and Claritas co-sponsored ENAiBLE trial has now recruited over 100 patients into
the study. Our collaboration with Artera to evaluate the ArteraAI Bladder Test,
which remains under development, illustrates the value of Photocure’s Cysview
registry as a rich dataset to support the validation of emerging diagnostic
tools. These initiatives enhance complementary aspects of care, from
visualization during cystoscopy to pathology-based insights that may inform
patient assessment and management,” Schneider expanded.

For 2026, Photocure now expects product revenue growth in the range of 10% to
12% on a constant currency basis (versus 8 to 11% previously) and continued
expansion of the adjusted EBITDA margin.

“We believe Photocure’s opportunity extends beyond any single product or
technology. By combining an established commercial franchise with capabilities
spanning early risk assessment, procedural detection and data-enabled patient
management, we are building a broader precision diagnostics platform in bladder
cancer. At the same time, we recognize the need to navigate an evolving
competitive environment while continuing to demonstrate the clinical value and
commercial resilience of our established franchise. Our commitment remains to be
disciplined, generate evidence that matters to clinicians and patients, and
convert our growing capabilities into sustainable commercial growth and long
-term shareholder value,” Schneider concludes.

Please find the full financial report and presentation enclosed.

Adjusted EBITDA and other alternative performance measures (APMs) are defined
and reconciled to the IFRS financial statements in the APM section of the third
quarter 2026 financial report on page 25.

The quarterly report and presentation will be published at 08:00 CET and will be
publicly available at www.photocure.com. Dan Schneider, CEO, Priyam Shah, VP of
Investor Relations and Dick Peters, VP of Finance & IT will host a live webcast
at 14:00 CET.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through:
Photocure Webcast Q3 2026

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Email: ds@photocure.com

Priyam Shah

Vice President Investor Relations

Tel: +1 717 6815 072

Email: priyam.shah@photocure.com

Geir Bjørlo

Corporate Communications (Norway)
Tel: +47 915 40 000

Email: geir.bjorlo@corpcom.no (geir.bjorlo@corpcom.no
)

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com/news

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Photocure ASA, on 28 October 2026
at 08:00 CET.

Kilde

[Haltopen]

For de som ønsker å ta et dypdykk.

CMS-1850-FC

Regulation No.: CMS-1850-FC

Title

Hospital Outpatient Prospective Payment- Final Rule with Comment Period

Year: 2027

Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots

This final rule with comment period revises the Medicare Hospital Outpatient Prospective Payment System (OPPS) and the Medicare Ambulatory Surgical Center (ASC) payment system for calendar year 2027 based on our continuing experience with these systems. We also describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment systems. In addition, this final rule with comment period updates and refines the requirements for the Hospital Outpatient Quality Reporting Program and the Ambulatory Surgical Center Quality Reporting Program. There are no changes to the Rural Emergency Hospital Quality Reporting Program. We finalized the expansion of the prior authorization requirement to include additional Botulinum Toxin Injection services. We also finalized implementation of certain provisions of the Consolidated Appropriations Act, 2026, for off-campus outpatient departments of a provider. In addition, this final rule with comment period announces notices of closure of teaching hospitals and opportunities to apply for available slots. Additionally, we finalized the policy that hospital accrediting organizations (AOs) with deeming authority may assess compliance with certain Emergency Medical Treatment and Labor Act (EMTALA) administrative requirements under 42 CFR 489.20 during accreditation and reaccreditation surveys.

https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices/cms-1850-fc

[Jubel]

Photocure småprat (PHO) 5

For at snakken om noget andet !!! Ser ud som der startes CIN3 forsøg op Oversat: Gode nyheder, klinisk rekruttering til non-kirurgisk behandling af CIN3 https://guba.eastmoney.com/news,688176,1793312474.html Dansken

[TekBot]

Photocure Provides Update on AssureMDx and Anticipated Medicare Coverage Timeline

Press release - Oslo, Norway, November 9, 2026 - Photocure ASA (OSE: PHO), the
Bladder Cancer Company, today provides an update on AssureMDxT and progress
since the acquisition of Vesica Health on June 4, 2026.
…

Vis børsmeldingen

Since closing the acquisition, Photocure has continued to advance the commercial
and reimbursement strategy for AssureMDx. Discussions with the relevant pricing
authorities have been encouraging, with indications of a potential reimbursement
level meaningfully above the assumptions included in Photocure’s initial
acquisition underwriting.

AssureMDx received FDA Breakthrough Device Designation in February 2026, further
supporting its clinical and regulatory positioning. Medicare pricing and
coverage are separate processes on different timelines. CMS expects to make a
final pricing determination before year-end 2026, and the resulting rate would
take effect January 1, 2027.

For coverage, Photocure’s planning assumption at the June 2026 acquisition was
Medicare coverage in 2028, following submission of additional clinical evidence.
The proposed Local Coverage Determination (“LCD”) from Novitas in May 2026
presented an opportunity for an earlier coverage determination. However,
AssureMDx was not yet included in the newly published LCD dated November 6,
2026, for urine-based biomarkers in patients with microhematuria. The
determination identifies additional clinical evidence required to support future
coverage reconsideration. Accordingly, the anticipated Medicare coverage
timeline remains aligned with the Company’s original acquisition assumptions.

AssureMDx is already supported by substantial published clinical validation
evidence, including prospective studies and microhematuria-specific analyses
demonstrating strong diagnostic performance. Novitas acknowledged the favorable
diagnostic performance and potential clinical utility of the existing evidence.
In the largest prospective study, AssureMDx demonstrated the potential to spare
89% of patients with microhematuria from cystoscopy, while all upper-tract
urothelial cancers in the study were detected. This evidence also contributed to
the inclusion of AssureMDx in the 2025 microhematuria guidelines issued by the
American Urological Association and the Society of Urodynamics, Female Pelvic
Medicine & Urogenital Reconstruction (AUA/SUFU), providing important independent
recognition of its clinical relevance.

Further clinical evidence generation is already underway. The SeARCH study is an
investigator-initiated randomized controlled trial conducted by Erasmus
University Medical Center (Erasmus MC) in the Netherlands, with Photocure
supporting the study as an industry sponsor and collaborator through its Vesica
Health entity. Supported by a grant from the Dutch Cancer Society, the study
involves approximately 1,100 patients with microhematuria and was initiated
prior to Photocure’s acquisition of Vesica Health. SeARCH is evaluating the
clinical utility of AssureMDx in guiding diagnostic decisions and reducing
unnecessary cystoscopies while maintaining patient safety.

In parallel, Photocure is finalizing the protocol for PATHWAY, a U.S. randomized
controlled clinical utility study designed to generate additional evidence in
the intended-use microhematuria population. Photocure intends to reengage with
the Novitas medical review team to discuss the evidence expectations outlined in
the published LCD, share its planned clinical development approach, and seek
feedback ahead of study initiation. Together, SeARCH and PATHWAY are designed to
generate high-quality randomized clinical utility evidence to support future
Medicare coverage reconsideration and potential updates to clinical guidelines.

“The proposed LCD in May 2026 presented an opportunity to accelerate Medicare
coverage, while our original development strategy anticipated the potential need
for additional randomized clinical utility evidence,” said Dan Schneider,
President and CEO of Photocure. “We are encouraged by the recognition of
AssureMDx’s diagnostic performance in the published clinical literature and
AUA/SUFU guidelines, as well as the progress we are making across our pricing
and commercial reimbursement strategy. With SeARCH already underway and PATHWAY
approaching initiation, we remain focused on generating the additional evidence
needed to support future Medicare coverage and advancing AssureMDx as part of
our broader uro-oncology precision diagnostics platform.”

The published LCD does not preclude commercialization of AssureMDx through
commercial payer and other reimbursement channels, which Photocure will continue
to pursue. Consistent with its original acquisition assumptions, the Company
continues to expect initial AssureMDx revenue in 2027.

For more information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Priyam Shah
Vice President Investor Relations
Tel : +17176815072
Email: priyam.shah@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer

Bladder cancer ranks as the 6[th] most common cancer worldwide - the 4[th] most
common in men - with 1 978 000 prevalent cases (5-year prevalence rate)[1a],
635 000 new cases and more than 227 000 deaths in 2024.[1b]
Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]

[1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [August 2026].
[2 ]Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3 ]Sievert KD et al. World J Urol 2009;27:295-300
[4 ]Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html

About AssureMDxT

AssureMDx is a non-invasive, urine-based molecular test designed to aid in the
early detection of bladder cancer in patients presenting with hematuria. Offered
as a laboratory-developed test (LDT) service, the test analyzes a combination of
DNA mutation and methylation biomarkers associated with bladder cancer. The test
has been validated in multiple prospective multicenter clinical studies,
demonstrating overall sensitivity of 96%, negative predictive value (NPV) of

99% and an area under the curve (AUC) of 0.96 for bladder cancer. The test is
included in the AUA/SUFU Microhematuria Guideline and received U.S. FDA
Breakthrough Device Designation in February 2026.

About Photocure ASA

Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news.

Important Information

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Copies of this announcement are not being made and
may not be distributed or sent into any jurisdiction in which such distribution
would be unlawful or would require registration or other measures. Persons into
whose possession this announcement or such other information should come are
required to inform themselves about and to observe any such restrictions.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “believe”, “expect”, “anticipate”,
“strategy”, “intends”, “estimate”, “will”, “may”, “continue”, “should” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although Photocure believes that these assumptions were reasonable
when made, these assumptions are inherently subject to significant known and
unknown risks, uncertainties, contingencies and other important factors which
are difficult or impossible to predict and are beyond its control.

The information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without notice.
Photocure undertakes no obligation to review, update, confirm, or to release
publicly any revisions to any forward-looking statements to reflect events that
occur or circumstances that arise in relation to the content of this
announcement.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of Photocure. Neither Photocure nor
its representatives accept any liability arising from the use of this
announcement.

This information is subject to the disclosure requirements pursuant to Section 5
-12 the Norwegian Securities Trading Act.

Kilde

[Jubel]

Oslo (Infront TDN Direkt): Photocure venter fortsatt første omsetning fra AssureMDx i 2027.

Det fremgår av en oppdatering fra selskapet mandag etter oppkjøpet av Vesica Health 4. juni i år.

Photocure la ved oppkjøpet til grunn at Medicare-dekning ville foreligge i 2028, etter fremleggelse av ytterligere klinisk dokumentasjon. Det foreslåtte vedtaket om lokal dekning (LCD) fra Novitas i mai 2026 åpnet en mulighet for en tidligere beslutning om dekning. AssureMDx var imidlertid ikke inkludert i den nylig publiserte LCD-en, datert 6. november 2026, som omhandler urinbaserte biomarkører hos pasienter med mikrohematuri, opplyses det.

-Det foreslåtte LCD-vedtaket i mai 2026 ga en mulighet til å fremskynde Medicare-dekning, samtidig som vår opprinnelige utviklingsstrategi tok høyde for et mulig behov for ytterligere dokumentasjon fra randomiserte kliniske studier, sier administrerende direktør Dan Schneider i Photocure.

Samtidig legger han til at Photocure er oppmuntret av anerkjennelsen av AssureMDx’ diagnostiske ytelse i publisert klinisk litteratur og i retningslinjene fra AUA/SUFU, samt fremgangen selskapet gjør med strategi for prissetting og kommersiell refusjon.

-Med SeARCH allerede i gang, og PATHWAY som nærmer seg oppstart, fortsetter vi å fokusere på å fremskaffe den ytterligere dokumentasjonen som trengs for å sikre fremtidig Medicare-dekning, og på å videreutvikle AssureMDx som en del av vår bredere plattform for presisjonsdiagnostikk innen uro-onkologi, sier han.

Den publiserte LCD-beslutningen utelukker ikke kommersialisering av AssureMDx gjennom kommersielle betalere og andre refusjonskanaler, noe Photocure vil fortsette å arbeide for. I tråd med de opprinnelige forutsetningene ved oppkjøpet, forventer selskapet fortsatt inntekter fra AssureMDx fra og med 2027>>, heter det i meldingen.